Blog
RSS FeedPosted by Michael Wonder on 04 Feb 2017
Most important breast cancer drug in two decades will not get NHS funding
3 February 2017 - A new drug described as one of the "most important" advances in treating breast cancer ...
Posted by Michael Wonder on 03 Feb 2017
Breast cancer drug costs too high in relation to benefits for routine NHS funding
3 February 2017 - NICE does not recommend breast cancer drug palbociclib (Ibrance, Pfizer) because its cost is too high in ...
Posted by Michael Wonder on 30 Jan 2017
Cancer drugs price rise 'costing NHS millions'
29 January 2017 - UK prices for generic cancer drugs have risen sharply in the past five years, restricting their ...
Posted by Michael Wonder on 25 Jan 2017
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation
25 January 2017 - NICE published guidance that recommended ibrutinib for chronic lymphocytic leukaemia in adults who have had at ...
Posted by Michael Wonder on 16 Jan 2017
Breast cancer patients' distress at withdrawal of Kadcyla
16 January 2017 - Terminal breast cancer patients have spoken of their distress after learning that a life-extending drug they ...
Posted by Michael Wonder on 11 Jan 2017
NICE publishes final guidance on the use of Keytruda for non-small-cell lung cancer
11 January 2017 - The guidance relates to the use of Keytruda (pembrolizumab) for treating PD-L1-positive non-small-cell lung cancer in adults ...
Posted by Michael Wonder on 06 Jan 2017
Trastuzumab emtansine and cost-based decision making
7 January 2017 - On 29 December 2016, the NICE in the UK invited comments on their draft guidance for use ...
Posted by Michael Wonder on 05 Jan 2017
Dying mum begs NHS to keep cancer drug free so she can live to see son go to school
5 January 2017 - Dying Bonnie Fox, 39, was diagnosed with secondary cancer in July 2015 only four months after her ...
Posted by Michael Wonder on 03 Jan 2017
NICE says liver cancer treatment to stay within the Cancer Drugs Fund, but not recommended for routine NHS use
30 December 2016 - The drug, sorafenib tosylate (Nexavar), which is used for treating advanced hepatocellular carcinoma, is not value for ...
Posted by Michael Wonder on 29 Nov 2016
NICE recommends 4p a day breast cancer drug
29 November 2016 - Women with a family history of breast cancer should be offered anastrozole, not tamoxifen, says NICE ...
Posted by Michael Wonder on 28 Nov 2016
Pfizer fears rough ride with NICE over breast cancer drug
28 November 2016 - Pfizer’s Ibrance breast cancer pill may have been a huge hit in the US, where it ...
Posted by Michael Wonder on 09 Oct 2016
Thousands of European melanoma patients lack access to new drugs
7 October 2016 - More than a quarter of European patients with advanced melanoma lack access to new treatments that ...
Posted by Michael Wonder on 04 Oct 2016
NICE published draft guidance on a new use for Keytruda
4 October 2016 - NICE has published draft guidance on the use of Keytruda (pembrolizumab) by patients with non-small-cell lung ...
Posted by Michael Wonder on 04 Oct 2016
NICE recommends new drug osimertinib for hundreds of people with lung cancer
4 October 2016 - Hundreds of people with lung cancer will now have access to new drug osimertinib, also known as ...
Posted by Michael Wonder on 29 Sep 2016
More on NICE recommendation of Imlygic
28 September 2016 - More on NICE's guidance on the use of talimogene laherparepvec for unresectable metastatic melanoma. ...